T1	condition 14 48	doxorubicin-induced Cardiotoxicity
T5	total-participants 1213 1215	32
T6	eligibility 1343 1400	breast cancer patients undergoing anthracycline treatment
T2	intervention 116 157	Docosahexaenoic Acid (DHA) and carvedilol
T3	control 1125 1139	double placebo
T4	outcome-Measure 1448 1500	changes in left ventricular ejection fraction (LVEF)
T7	outcome-Measure 1549 1592	changes in global longitudinal strain (GLS)
T9	outcome-Measure 1648 1701	elevation in serum biomarkers (hs-cTnT and NT-ProBNP)
T10	outcome-Measure 1707 1755	one electrocardiographic variable (QTc interval)
T8	outcome-Measure 1800 1810	biomarkers
T11	outcome-Measure 1819 1861	occurrence of major adverse cardiac events
